XRTX - XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023 | Benzinga
CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology (the "ASN"). The abstract entitled "The Effect of Lowering Uric Acid with a Xanthine Oxidase Inhibitor on PKD in Mice" was reviewed by the ASN review panel for scientific merit and novel discoveries. The studies were conducted at the University of Colorado in the independent laboratory of Dr. Charles Edelstein and were sponsored by XORTX and will be presented at Kidney Week during the Session Title: Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis.
The abstract outlines study results from a mouse model of polycystic kidney disease challenged with low to moderate circulating uric acid. The results of the study support the concept that even moderate to high, soluble, but not saturating, circulating uric acid can accelerate kidney expansion rate and functional decline and that a mechanism of injury with uric acid crystals is not necessary for health consequences in polycystic kidney disease. The results further suggest that threshold uric acid lowering needs to be achieved for optimal therapeutic benefit. The study also identifies a novel inflammatory profile as a possible mechanism of injury inducing an increased cyst index and kidney enlargement. XORTX will provide further details of the study at the time of the presentation during the first week of November at the ASN meeting scheduled for November 2, 2023.
Dr. Allen Davidoff, CEO of XORTX, stated, "We are pleased to have supported this new research on the mechanisms of injury that can modulate the progression of ADPKD and that this pioneering research has been selected for presentation at the ASN annual meeting during Kidney Week 2023. XORTX granted patents and additional patent applications supporting the XRx-008 program are wholly owned by XORTX."
About the American Society of Nephrology – Kidney Week
ASN represents more than 21,000 kidney health professionals working to help people ...